A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer|Squamous Cell Lung Cancer|Non-squamous Cell Lung Cancer With KRAS Mutations|Non-squamous Cell Lung Cancer With Wild-type KRAS
Interventions: DRUG: AZD2014|DRUG: AZD6244
Sponsor: Queen Mary University of London
Collaborators: Cancer Research UK|AstraZeneca